source
- Create Medicines secures $122M Series B to advance in vivo CAR-T therapiesCreate Medicines, a Cambridge biotech, announced a $122 million Series B financing to expand its in vivo CAR-T cell therapy platform targeting cancer and autoimmune diseases. The round was co-led…
- Phase III trial shows tebentafusp doubles five-year survival in untreated metastatic uveal melanomaA Phase III study of tebentafusp in patients with previously untreated metastatic uveal melanoma reported that five-year overall survival was roughly twice that of the control group. The trial als…